"GlycoVision results featured at ESMO 2024: read the interview here to learn how InterVenn is powering new prognostic and predictive biomarkers!
Back to blog list
November 18, 2022
Fucose signatures in peripheral blood glycoproteins are associated with reduced clinical benefit of immune-checkpoint inhibitors in metastatic melanoma

Get in touch